Business ❯Market Competition ❯Pharmaceutical Industry ❯Competitor Analysis
The first nonpeptide oral GLP-1 therapy, orforglipron, matches injectable drugs in weight-loss and glucose-control efficacy, with FDA filings planned for late 2025.
